Lexicon Pharmaceuticals, Inc.
LXRX· Nasdaq
LXRXLexicon Pharmaceuticals, Inc.
Filed Mar 1, 2018 · 10-K · 60 days after period end · 0001062822-18-000008
derived · Computed from the longer spans the company filed.
| Metric | Q4 2016dderived from reported figures | Q4 2015 | Q4 2014 | Q4 2013 |
|---|---|---|---|---|
| Revenue | -$41.83M | $23.04M | $127.28M | $21.48M |
| Net Income | -$28.38M | -$32.42M | $86.75M | -$2.93M |
| EPS Diluted | — | -$0.31 | $0.76 | -$0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
ended Dec 31, 2017 · filed Mar 1, 2018 · 60 d after period end
